Aim Immunotech Inc Revenue Growth Rates (AIM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aim Immunotech Inc   (NYSEAMER: AIM)
 

AIM's Revenue Growth by Quarter and Year

Aim Immunotech Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AIM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.02
FY 0.02

AIMs Annual Revenue
Aim Immunotech Inc 's Revenue in the fiscal year 2025 $ 0.09 millions
Aim Immunotech Inc 's Revenue in the fiscal year 2024 $ 0.17 millions
Aim Immunotech Inc 's Revenue in the fiscal year 2023 $ 0.20 millions
Aim Immunotech Inc 's Revenue in the fiscal year 2022 $ 0.14 millions
Aim Immunotech Inc 's Revenue in the fiscal year 2021 $ 0.14 millions




AIM Revenue first quarter 2026 Y/Y Growth Comment
Aim Immunotech Inc achieved in the first quarter 2026, above Company average Revenue improvement of 10% year on year, to $ 0.02 millions.

Looking into first quarter 2026 results within Biotechnology & Pharmaceuticals industry 40 other companies have achieved higher Revenue growth. While Aim Immunotech Inc ' s Revenue increase of 10% ranks overall at the positon no. 2698 in the first quarter 2026.


AIM Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -60 % -28.57 % 16.67 %
3rd Quarter September - -25 % -20 % 150 %
2nd Quarter June - -40 % 25 % 33.33 %
1st Quarter March 10 % -50 % -20 % 66.67 %
FY   - -44.44 % -14.29 % -

Financial Statements
Aim Immunotech Inc 's first quarter 2026 Revenue $ 0.02 millions AIM's Income Statement
Aim Immunotech Inc 's first quarter 2025 Revenue $ 0.02 millions Quarterly AIM's Income Statement


AIM Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -33.33 % 25 % 40 %
3rd Quarter September - 0 % -20 % 25 %
2nd Quarter June - 50 % 25 % -20 %
1st Quarter March 10 % -60 % -42.86 % -16.67 %
FY (Year on Year)   - -44.44 % -14.29 % -


Back to AIM Growth rate Comparisons >> Back to AIM Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #390
Overall #2698

Revenue Y/Y Growth Statistics
High Average Low
43.26 % -37.21 % -148.13 %
(Dec 31 2023)   (Sep 30 2022)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #390
Overall #2698
Revenue Y/Y Growth Statistics
High Average Low
43.26 % -37.21 % -148.13 %
(Dec 31 2023)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aim Immunotech Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
171.43 % 8.61 % -64.44 %
(Dec 31 2022)  


AIM's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Aim Immunotech Inc disclosed growth in Revenue from the fourth quarter by 10% to $ 0.02 millions, from $ 0.02 millions achived in the previous reporting period.

Within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Aim Immunotech Inc 's Revenue growth quarter on quarter, overall rank is 923.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #23
Healthcare Sector #138
Overall #923
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #23
Healthcare Sector #138
Overall #923
Revenue Q/Q Growth Statistics
High Average Low
171.43 % 8.61 % -64.44 %
(Dec 31 2022)  


AIM's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Aim Immunotech Inc disclosed growth in Revenue from the fourth quarter by 10% to $ 0.02 millions, from $ 0.02 millions achived in the previous reporting period.

Within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Aim Immunotech Inc 's Revenue growth quarter on quarter, overall rank is 923.


Aim Immunotech Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 0.09 $ 0.09 $ 0.11 $ 0.12 $ 0.15
Y / Y Revenue Growth (TTM) -35.62 % -48.24 % -41.05 % -39.8 % -24.35 %
Year on Year Revenue Growth Overall Ranking # 3473 # 2732 # 1875 # 562 # 508
Seqeuential Revenue Change (TTM) 6.82 % -21.43 % -7.44 % -17.12 % -14.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 3310 # 2633 # 2620 # 1644 # 2561


Cumulative Revenue growth Comment
Aim Immunotech Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Aim Immunotech Inc 's annual Revenue fall would be -35.62% year on year to $0 millions.

In the Healthcare sector 463 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2732 to 3473.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 464
Overall # 3473

Revenue TTM Y/Y Growth Statistics
High Average Low
44.78 %
 -19.59 %
-148.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 440
S&P 500 # 3310
Cumulative Revenue growth Comment
Aim Immunotech Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Aim Immunotech Inc 's annual Revenue drop would be -35.62% year on year to $0 millions.

In the Healthcare sector 463 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2732 to 3473.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 464
Overall # 3473

Revenue TTM Y/Y Growth Statistics
High Average Low
44.78 %
-19.59 %
-148.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 440
S&P 500 # 3310




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AIM's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Artivion Inc 17.11%$ 17.115 millions
Harmony Biosciences Holdings inc 16.95%$ 16.946 millions
Karyopharm Therapeutics Inc 16.83%$ 16.828 millions
Edwards Lifesciences Corporation16.71%$ 16.706 millions
Cryoport inc 16.47%$ 16.467 millions
Electromed Inc 15.85%$ 15.851 millions
Penumbra Inc15.62%$ 15.616 millions
Innovage Holding Corp 15.49%$ 15.495 millions
Mannkind Corporation15.08%$ 15.082 millions
Theravance Biopharma inc 15.02%$ 15.018 millions
Dexcom Inc 14.99%$ 14.990 millions
Enanta Pharmaceuticals Inc14.96%$ 14.960 millions
Elanco Animal Health Incorporated14.92%$ 14.920 millions
Biofrontera Inc 14.87%$ 14.870 millions
Biolife Solutions Inc 14.85%$ 14.849 millions
Lineage Cell Therapeutics Inc 14.85%$ 14.847 millions
Repligen Corp14.83%$ 14.827 millions
Biorestorative Therapies Inc 14.60%$ 14.596 millions
Pro dex Inc 14.56%$ 14.557 millions
Atricure Inc 14.42%$ 14.420 millions
Idexx Laboratories Inc14.26%$ 14.259 millions
Livanova Plc14.20%$ 14.197 millions
Ligand Pharmaceuticals Incorporated14.09%$ 14.093 millions
Exagen Inc 13.77%$ 13.767 millions
Concentra Group Holdings Parent Inc 13.74%$ 13.740 millions
Immunocore Holdings Plc13.63%$ 13.630 millions
Petvivo Holdings Inc 13.33%$ 13.326 millions
Alphatec Holdings Inc 13.30%$ 13.302 millions
Anika Therapeutics Inc 12.91%$ 12.912 millions
Qhslab Inc 12.90%$ 12.901 millions


About Aim Immunotech Inc Revenue Growth Rates (AIM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.